AR035927A1 - Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr - Google Patents
Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabrInfo
- Publication number
- AR035927A1 AR035927A1 ARP010105312A ARP010105312A AR035927A1 AR 035927 A1 AR035927 A1 AR 035927A1 AR P010105312 A ARP010105312 A AR P010105312A AR P010105312 A ARP010105312 A AR P010105312A AR 035927 A1 AR035927 A1 AR 035927A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- inhibition
- synthesis
- amyloid peptide
- benzazepin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000005764 inhibitory process Effects 0.000 title abstract 4
- 230000015572 biosynthetic process Effects 0.000 title abstract 3
- 238000003786 synthesis reaction Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 2
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 abstract 1
- -1 Lactam compound Chemical class 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24955200P | 2000-11-17 | 2000-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035927A1 true AR035927A1 (es) | 2004-07-28 |
Family
ID=22943982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105312A AR035927A1 (es) | 2000-11-17 | 2001-11-14 | Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr |
Country Status (33)
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7468365B2 (en) | 2000-11-17 | 2008-12-23 | Eli Lilly And Company | Lactam compound |
| UA74849C2 (en) * | 2000-11-17 | 2006-02-15 | Lilly Co Eli | Lactam |
| CA2603320A1 (en) | 2005-04-08 | 2006-10-19 | Daiichi Sankyo Company, Limited | Pyridylmethylsulfone derivative |
| ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
| EP1985615A4 (en) | 2006-01-31 | 2011-12-14 | Api Corp | PROCESS FOR THE PREPARATION OF BENZAZEPINONE |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| CL2008002060A1 (es) * | 2007-07-16 | 2008-11-21 | Wyeth Corp | Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras. |
| KR101136260B1 (ko) | 2007-08-14 | 2012-04-19 | 일라이 릴리 앤드 캄파니 | 감마-세크레타제 억제제로서의 아제핀 유도체 |
| TW200920362A (en) | 2007-09-11 | 2009-05-16 | Daiichi Sankyo Co Ltd | Alkylsulfone derivatives |
| CN101945853B (zh) | 2007-12-21 | 2014-08-20 | 配体药物公司 | 选择性雄激素受体调节剂(sarm)及其应用 |
| WO2009128057A2 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
| EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | HAMMER OF ACT ACTIVITY |
| CA2777043C (en) | 2009-10-14 | 2015-12-15 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| CN103068980B (zh) | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制 |
| RU2745848C2 (ru) | 2010-08-17 | 2021-04-01 | Сирна Терапьютикс, Инк. | ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
| EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| WO2012040444A2 (en) * | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Treatment of patients with incipient alzheimer's disease |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| CN102690231B (zh) * | 2012-04-11 | 2014-07-09 | 南京友杰医药科技有限公司 | 治疗阿尔茨海默病潜在药物司马西特的合成方法 |
| EP3919620A1 (en) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| EP2892506B1 (en) | 2012-09-07 | 2021-11-03 | Massachusetts Eye & Ear Infirmary | Treating hearing loss with the gamma-secretase inhibitor ly411575 |
| CA2884309A1 (en) | 2012-09-07 | 2014-03-13 | Massachusetts Eye And Ear Infirmary | Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity |
| CA2882950A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| SMT201700595T1 (it) | 2012-11-28 | 2018-03-08 | Merck Sharp & Dohme | Composizioni e metodi per trattare il cancro |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| EP2987496B1 (en) | 2013-04-19 | 2018-08-08 | National University Corporation Okayama University | Treatment agent for cognitive disorders, induced by amyloid -protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3613418A1 (en) | 2014-01-17 | 2020-02-26 | Ligand Pharmaceuticals, Inc. | Methods and compositions for modulating hormone levels |
| EP3212773B1 (en) | 2014-10-29 | 2021-09-15 | Massachusetts Eye and Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
| KR102362222B1 (ko) | 2016-05-16 | 2022-02-11 | 더 제너럴 하스피탈 코포레이션 | 폐 상피 공학에서 인간 기도 줄기 세포 |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US11590152B2 (en) | 2018-01-26 | 2023-02-28 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss |
| CA3108388A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033285A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| AU2020257397B2 (en) | 2019-04-19 | 2026-02-26 | Ligand Pharmaceuticals Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| EP4076460B1 (en) | 2019-12-17 | 2026-01-21 | Merck Sharp & Dohme LLC | 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer |
| EP4076459B1 (en) | 2019-12-17 | 2026-04-29 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| ES3022307T3 (en) | 2019-12-17 | 2025-05-28 | Merck Sharp & Dohme Llc | Prmt5 inhibitors |
| ES3074517T3 (en) | 2019-12-17 | 2026-07-21 | Merck Sharp & Dohme Llc | 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease |
| CN120225528A (zh) | 2022-09-02 | 2025-06-27 | 默沙东有限责任公司 | 依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途 |
| KR20250079227A (ko) | 2022-10-25 | 2025-06-04 | 머크 샤프 앤드 돔 엘엘씨 | 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도 |
| KR20250116773A (ko) | 2022-12-14 | 2025-08-01 | 머크 샤프 앤드 돔 엘엘씨 | 아우리스타틴 링커-페이로드, 제약 조성물, 및 그의 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9711537B (en) * | 1996-12-23 | 1998-06-25 | Athena Neurosciences Inc Eli L | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds. |
| AU4707999A (en) * | 1998-06-22 | 2000-01-10 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| AU1569501A (en) * | 1999-11-09 | 2001-06-06 | Eli Lilly And Company | Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis |
| DE60135489D1 (de) * | 2000-11-17 | 2008-10-02 | Lilly Co Eli | Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung |
| UA74849C2 (en) * | 2000-11-17 | 2006-02-15 | Lilly Co Eli | Lactam |
| UA77165C2 (en) * | 2000-11-17 | 2006-11-15 | Lilly Co Eli | (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition |
-
2001
- 2001-05-11 UA UA2003054408A patent/UA74849C2/uk unknown
- 2001-11-05 PT PT01989070T patent/PT1341531E/pt unknown
- 2001-11-05 AU AU2002243192A patent/AU2002243192B2/en not_active Ceased
- 2001-11-05 DZ DZ013453A patent/DZ3453A1/fr active
- 2001-11-05 EA EA200300580A patent/EA005954B1/ru not_active IP Right Cessation
- 2001-11-05 DK DK01989070T patent/DK1341531T3/da active
- 2001-11-05 CN CNA018221009A patent/CN1486184A/zh active Pending
- 2001-11-05 US US10/416,771 patent/US20050261495A1/en not_active Abandoned
- 2001-11-05 WO PCT/US2001/027799 patent/WO2002047671A2/en not_active Ceased
- 2001-11-05 CA CA2427227A patent/CA2427227C/en not_active Expired - Fee Related
- 2001-11-05 MX MXPA03004292A patent/MXPA03004292A/es active IP Right Grant
- 2001-11-05 BR BR0115427-3A patent/BR0115427A/pt not_active IP Right Cessation
- 2001-11-05 HR HR20030383A patent/HRP20030383B1/xx not_active IP Right Cessation
- 2001-11-05 IL IL15596001A patent/IL155960A0/xx unknown
- 2001-11-05 ES ES01989070T patent/ES2278804T3/es not_active Expired - Lifetime
- 2001-11-05 PL PL362688A patent/PL212199B1/pl unknown
- 2001-11-05 JP JP2002549245A patent/JP4116437B2/ja not_active Expired - Fee Related
- 2001-11-05 SK SK559-2003A patent/SK288065B6/sk not_active IP Right Cessation
- 2001-11-05 HU HU0301842A patent/HU228117B1/hu not_active IP Right Cessation
- 2001-11-05 SI SI200130701T patent/SI1341531T1/sl unknown
- 2001-11-05 CZ CZ20031351A patent/CZ20031351A3/cs unknown
- 2001-11-05 KR KR1020037006721A patent/KR100819679B1/ko not_active Expired - Fee Related
- 2001-11-05 NZ NZ525854A patent/NZ525854A/en not_active IP Right Cessation
- 2001-11-05 DE DE60126132T patent/DE60126132T2/de not_active Expired - Lifetime
- 2001-11-05 EP EP01989070A patent/EP1341531B1/en not_active Expired - Lifetime
- 2001-11-05 AU AU4319202A patent/AU4319202A/xx active Pending
- 2001-11-12 TW TW090128005A patent/TWI305204B/zh not_active IP Right Cessation
- 2001-11-14 AR ARP010105312A patent/AR035927A1/es not_active Application Discontinuation
- 2001-11-15 MY MYPI20015236A patent/MY134559A/en unknown
- 2001-11-16 PE PE2001001142A patent/PE20020802A1/es not_active Application Discontinuation
-
2003
- 2003-05-13 EC EC2003004600A patent/ECSP034600A/es unknown
- 2003-05-15 IL IL155960A patent/IL155960A/en not_active IP Right Cessation
- 2003-05-15 ZA ZA200303789A patent/ZA200303789B/en unknown
- 2003-05-16 NO NO20032236A patent/NO324324B1/no not_active IP Right Cessation
-
2007
- 2007-03-09 CY CY20071100331T patent/CY1106366T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2427227A1 (en) | Lactam compound | |
| IL171977A (en) | Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same | |
| CA2426703A1 (en) | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | |
| AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| MXPA03005464A (es) | Agentes antivirales. | |
| CY1115484T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson | |
| DE50203456D1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| AR004700A1 (es) | 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento | |
| ATE213633T1 (de) | Lamotrigin haltiges arzneimittel | |
| SE0102055D0 (sv) | New Compounds | |
| ECSP066878A (es) | [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa | |
| SE0102440D0 (sv) | New compound | |
| DE69928806D1 (de) | (-)-pseudoephedrin als sympathomimetisches arzneimittel | |
| AR035006A1 (es) | Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento. | |
| RU2007104774A (ru) | Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы | |
| AR029666A1 (es) | Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina | |
| AR036009A1 (es) | Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica | |
| UY26595A1 (es) | Formulaciones de entecavir de dosis bajas y uso | |
| AR034142A1 (es) | Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion | |
| AR014082A1 (es) | Concentrado oral de sertralina | |
| ES2170649B1 (es) | Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica. | |
| GEP20053512B (en) | S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders. | |
| DE50202865D1 (de) | Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel | |
| PT1451184E (pt) | Compostos diméricos e sua utilização como agentes antivirais | |
| AR038847A1 (es) | Uso del compuesto n-(3,5-dicloro-2-metoxi-fenil) -4-metoxi-3-piperazin-1-il-bencenosulfonamida para la elaboracion de una composicion farmaceutica y dicha composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |